FGD4 overexpression has been observed in pancreatic neuroendocrine neoplasms (Shahid et al. 2019) and expression of FGD4 positively correlates with the aggressive phenotype of prostate cancer (Bossan et al. 2018). Here, FGD4 is linked to prostate cancer.